Adverse drug reaction (ADR) induces iatrogenic harm, costs a lot in cancer care continuum. However, there is a dearth of concrete evidence regarding its prevalence in a resource-limited setting. Thus, the present systematic review set out to cohere the available evidences.
Design
systematic review and meta-analysis.
Data sources
PubMed, CINAHL, Web of Science, EMBASE, and Google Scholar databases were searched.
Eligibility criteria
observational studies focused on the magnitude of chemotherapy-related ADRs among patients with cancer were eligible.
Data extraction and synthesis
Primary studies quality was appraised employing the Joanna Briggs Institute (JBI) Checklist. A random-effects meta-analysis employing the meta package for proportions (Metaprop) was conducted. Heterogeneity was assessed with Cochrane's Q test and I2 statistic, and publication bias with Egger's test and a funnel plot. Protocol was registered at PROSPERO with a reference number – [CRD42024546390].
Results
Out of 1507 identified studies, 7 were met the inclusion criteria. The pooled prevalence of ADRs was 43% [95% CI: 35%, 50%, I2 = 87.06%]. Age > 65 years (p = 0.001), standard anticancer dose (p = 0.015), concomitant medication (p < 0.000), etoposide (p < 0.002), mercaptopurine (p < 0.041), doxorubicin (p < 0.005) and polychemotherapy (p < 0.001) were the predictors of chemotherapy-related ADRs.
Conclusion
Chemotherapy-related ADRs are quite common among patient with cancer in Ethiopia. Consequently, healthcare providers should pay closer attention to ADR assessment and monitoring by using tailored screening tools, with special emphasis on older adults, those receiving standard anticancer doses, concomitant medications, polychemotherapy, or regimens containing etoposide, mercaptopurine, or doxorubicin to improve safety and efficacy of chemotherapies.
MorampudiM. Review on: adverse drug reactions of chemotherapy drugs. J Pharmacol Toxicol Stud2016; 4(3): 85–93.
2.
LavanAHO’mahonyDBuckleyM, et al.Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. The Oncologist2019; 24(9): e968–e977: DOI:10.1634/theoncologist.2018-0476
3.
AngamoMTChalmersLCurtainCM, et al.Adverse-drug-reaction-related hospitalisations in developed and developing countries: A review of prevalence and contributing factors. Drug Saf2016; 39(9): 847–57. DOI:10.1007/s40264-016-0444-7
4.
World Health Organization Technical Report Services. International drug monitoring: the role of national centres. Report of a WHO meeting. 4981972, 1–25.
5.
LentzRBensonABKircherS. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol2019; 120(1): 85–92. DOI: 10.1002/ jso.25374
6.
JiangHLinYRenW, et al.Adverse drug reactions and correlations with drug-drug interactions: a retrospective study of reports from 2011 to 2020. Front Pharmacol2022; 13: 923939. DOI:10.3389/fphar.2022.923939
7.
World Health Organization. Medication without harm-WHO global patient safety challenge. Geneva: World Health Organization, 2017.
8.
TorresHAMulanovichV. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis2014; 59(1): 106–114. DOI:10.1093/cid/ciu 174
9.
YadesaTMKitutuFETamukongR, et al.Prevalence, incidence, and characteristics of adverse drug reactions among older adults hospitalized at Mbarara regional referral hospital, Uganda: a prospective cohort study. Clin Interv Aging2021; 16: 1705–1721. DOI:10.2147/CIA.S332251
10.
KrishnakumarKLManjuR. Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. Int J Pharm Sci Res2013; 4: 386–391.
11.
WilsonRMRuncimanWBGibberdRW, et al.The quality in Australian health care study. Med J Aust1995; 163(6): 458–471.
12.
EFDA. Assessment of health care providers’ knowledge, attitude and practice on adverse drug reaction (ADR) reporting and its monitoring. EFDA, Addis Ababa, Ethiopia, 2008.
13.
LauPMStewartKDooleyMJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother2003; 37(2): 303–304.
14.
PageMJMoherDBossuytPM, et al.PRISMA 2020 Explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J2021; 372(n160). DOI:10.1136/bmj.n160
15.
ManjhiPKSinghMPKumarM. Causality, severity, preventability and predictability assessments scales for adverse drug reactions: a review. Cureus2024; 16: e59975. DOI:https://doi.org/10.7759/cureus.59975
16.
EndNote. Version 20. Philadelphia, PA: Clarivate, 2013.
17.
The Joanna Briggs Institute (JBI). The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: Critical appraisal checklist for analytical cross sectional studies. 2017.
18.
The Joanna Briggs Institute (JBI). The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: JBI critical appraisal checklist for cohort studies. 2017.
19.
Cochrane Group. Data collection form for intervention reviews: RCTs and non-RCTs. 2014. Accessed May 11, 2024.
20.
STATA Statistical Software. Version Release 172021.
DeeksJJHigginsJPAltmanDG.Chapter 10: Analysing data and undertaking meta-analyses. In: HigginsJPThomasJ, and ChandlerJ, et al. (eds) Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane Group; 2024, pp.241–279.
BelachewSAErkuDAMekuriaAB, et al.Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University referral hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf2016; 8: 83–90. DOI:https://doi.org/10.2147/dhps.S116924
25.
KefaleBEngidawMTTesfaD, et al.Clinical pattern and drug-related problems among colorectal cancer patients at oncology center in Ethiopia A hospital-based study. SAGE Open Med2022; 10: 1–11. DOI:https://doi.org/10.1177/205031212211 31691
26.
DeguAKebedeK. Drug-related problems and its associated factors among breast cancer patients at the university of Gondar comprehensive specialized hospital, Ethiopia: a hospital-based retrospective cross-sectional study. J Oncol Pharm Pract2021; 27: 88–98. DOI:https://doi.org/10.1177/1078155220914710
27.
WorkalemahuGAbdelaOAYeniMK. Chemotherapy-related adverse drug reaction and associated factors among hospitalized paediatric cancer patients at hospitals in North-West Ethiopia. Drug Healthc Patient Saf2020; 12: 195–205. DOI:https://doi.org/10.2147/ DHPS.S254644
28.
KefaleBTadegeMTesfaD, et al.Management pattern and medication-related harms and its predictors in colorectal cancer patients: an institutional-based retrospective study. Front Oncol2023; 13: 1253845. DOI:https://doi.org/10.3389/fonc.2023.1253845
29.
KefaleBEngidawMTTesfaD, et al.Management practice and drug related problems and its contributing factors among cervical cancer patients at oncologic center in Ethiopia: a hospital-based retrospective study. Ther Clin Risk Manag2022; 18: 643–655. DOI:https://doi.org/10.2147/TCRM.S364923
30.
SisayEAEngidaworkEYesufTA, et al.Drug related problems in chemotherapy of cancer patients. J Cancer Sci Therapeutics2015; 7: 55–59. DOI:https://doi.org/10.4172/1948-5956.1000325
31.
HartwigSCSiegelJSchneiderPJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health-Syst Pharm1992; 49: 2229–2232. DOI:https://doi.org/10.1093/ajhp/49.9.2229
32.
National Cancer Institute. Common terminology criteria for adverse events (CTCAE)v 4.0. 2010.
33.
FujiwaraTKenmotsuHNaitoT, et al.The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum. Cancer Chemother Pharmacol2017; 79: 1229–1237. DOI:10.1007/s00280-017-3324-7
34.
AagaardLStrandellJMelskensL, et al.Global patterns of adverse drug reactions over a decade. Drug Saf2012; 35: 1171–1182. DOI:https://doi.org/10.1 007/bf03262002
35.
EshetieTCHailemeskelBMekonnenN, et al.Adverse drug events in hospitalized children at Ethiopian University Hospital a prospective observational study. BMC Pediatr2015; 15: 1–8. DOI:https://doi.org/10.1186/s12887-015-0401-0
36.
LaurenceL.BruntonBCK.Pharmacotherapy of neoplastic disease. In: WellsteinA (ed.) Goodman & Gilman's the pharmacological basis of therapeutics14th edition ed. New York: McGraw Hill LLC; 2023, pp.1337–1342.
37.
WahlangJBLaishramPDBrahmaDK, et al.Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf2017; 8: 61–66. DOI:https://doi.org/10.1177/20420986166725 72
38.
HadiaRJoshiDBhilD, et al.Incidence of adverse drug reactions among elderly patients: a systematic review and meta-analysis. J Sci Soc2022; 49: 91–102. DOI:https://doi.org/10.4103/jss.jss_50_22
39.
InsaniWNWhittleseaCAlwafiH, et al.Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS ONE2021; 16. DOI:10.1371/journal.pone.0252161
40.
SinghSDhasmanaDBishtM, et al.Pattern of adverse drug reactions to anticancer drugs: a quantitative and qualitative analysis. Indian J Med Paediatr Oncol2017; 38: 140–145. DOI:https://doi.org/10.4103/ijmpo.ijmpo_18_16
41.
TamangRBharatiLKhatiwadaAP, et al.Pattern of adverse drug reactions associated with the use of anticancer drugs in an oncology-based hospital of Nepal. JMA J2022; 4: 416–426. DOI:https://doi.org/10.31662/jmaj.2021-0015
42.
WangYZhouSYangF, et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol2019; 5: 1008–1019. DOI:https://doi.org/10.1001/jamaoncol.2019.0 393
43.
ZhuYLiuKWangK, et al.Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer2023; 129: 283–295. DOI:https://doi.org/10.1002/cncr.34507
44.
KatjaMHakkarainenKHMax PetzoldHS. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions –a meta-analysis. PLoS ONE2012; 7: 1–9. DOI:10.1371/journal.pone.0033236
45.
ParandeFAnandAKhapardeM, et al.Chemotherapy-Induced adverse drug reactions in pediatric oncology. J Young Pharm2018; 10: 340–343. DOI:https://doi.org/10.5530/jyp.2018.10.75
46.
PanditSVermaMMishraPS. A prospective study of adverse drug reactions associated with chemotherapy in patients of carcinoma head and neck in Government Cancer Hospital Indore, India. Int J Basic Clin Pharmacol2020; 9(6): 897–901. DOI:10.18203/2319-2003.ijbcp20202178
47.
LiuYLiuXXiaB, et al.The application of global trigger tool in monitoring antineoplastic adverse drug events: a retrospective study. Front Oncol2024; 14(1230514): 1–10. DOI:10.3389/fonc.2024.1230514
48.
GeorgeDMPalattyPL. Pattern of adverse drug reactions to anticancer drugs at an apex hospital in south India: a retrospective study. Indian J Pharm Pharmacol2022; 9: 191–195. DOI:https://doi.org/10.18231/j.ijpp.2022.034
49.
Sneegdha PoddarRSSultanaRAkborMM, et al.Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J Pharmaceutical Sci2009; 8: 11–16.
50.
Lorena Medreiros de Almeida Mateus, Jaqueline Almeida Guimarães Barbosa, Miguir Terezinha Vieccelli Donosco, Beatriz Regina Lima de Aguiar PEDdR, Giovana de Paula Rezende Simino. Nursing diagnoses related to the potential adverse effects of antineoplastic chemotherapyia. Enfermería Global2021; 20: 61–107. DOI:https://doi.org/10.6018/ eglobal.450831
51.
RiveRa-LunaRcáRdenas-caRdósRveLasco-HidaLgoL, et al.A profile of the adverse effects of antineoplastic agents for the treatment of children with cancer. J Cancer Ology2015; 2(1): 7–14.
52.
StrumiaMPerrinM-LPatras de CampaignoE, et al.Dermatological adverse drug reactions of anticancer drugs: international data of pharmacovigilance: vigiBase®. Therapies2022; 77: 219–227. DOI:https://doi.org/10.1016/j.therap.2021.12.006
53.
GoudaSSaadAAbbassiM, et al.Adverse drug reactions of antineoplastic and immunomodulating agents reported to the Egyptian pharmaceutical vigilance center. Bull Fac Pharm, Cairo Univ2019; 57: 96–103. DOI:https://doi.org/10.21608 /bfpc.2019.7213.1000
54.
Sapan Kumar BeheraCRKGunaseelanVDubashB, et al.Chemotherapy induced adverse drug reactions in cancer patients in a tertiary care hospital in south India. J Young Pharm2017; 9: 593–597. DOI:https://doi.org/10.5530/jyp.2017.9.113
55.
George SnehaSSimhadriKSubeeshVK, et al.Predictors of adverse drug reactions in geriatric patients: an exploratory study among cancer patients. South Asian J Cancer2019; 8: 130–133. DOI:https://doi.org/10.4103/sajc.sajc_218_18
56.
ChoulliFTafenziHAHattimyFE, et al.Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized breast cancer: a descriptive study: Mohammed VI University Hospital, Medical Oncology Department, Marrakech, Morocco. BMC Cancer2024; 24: 17. DOI:https://doi.org/10.1186/s12885-023-11616-5
57.
MohamedMRMohileSGJubaKM, et al.Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer2023; 129: 1096–1104. DOI:https://doi.org/10.1002/cncr.34642
58.
ShresthaSShresthaSKhanalS. Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. Aging Med (Milton)2019; 2: 42–49. DOI:https://doi.org/10.1002/agm2.12051
59.
WallaceKJCantorAOvercashJ, et al.Influence of concomitant medications on toxicity from chemotherapy in elderly patients. Focus on cytochrome P-450 inhibition and protein binding effects. J Clin Oncol2005; 23: 8025–8025. DOI:https://doi.org/10.1200/jco.2005.23.16_suppl.8025
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
